Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Clinical Stage II Esophageal Adenocarcinoma AJCC v8: early-phase trial registry

6 of 11 indexed Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 6 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Clinical Stage II Esophageal Adenocarcinoma AJCC v8: 11 US clinical trials tracked, 6 recruiting.

Clinical Stage II Esophageal Adenocarcinoma AJCC v8 is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is NRG Oncology, running 2 of these trials.

Enrollment posture brief

Registry condition clinical-stage-ii-esophageal-adenocarcinoma-ajcc-v8

OPEN 6 | RECR 55% | LATE 1 | EARLY 6 | RANK #1577 | SPON 2

Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)

Acute Pancreatitis81.8%Clinical Stage II Esopha (th…55%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Clinical Stage II Esophageal Adenocarcinoma AJCC v8

Clinical Stage II Esophageal Adenocarcinoma AJCC v8 lists 6 open slots (55% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Clinical Stage II Esophageal Adenocarcinoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Clinical Stage II Esophageal Adenocarcinoma AJCC v8 is recruiting above its size-band peers.

    6 of 11 indexed trials (54.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Clinical Stage II Esophageal Adenocarcinoma AJCC v8 research.

    NRG Oncology accounts for 2 of 11 trials (18.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.

  4. Clinical Stage II Esophageal Adenocarcinoma AJCC v8 research is mostly interventional.

    9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 31

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 3 300 participants

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

NRG Oncology

NCT03801876

RECRUITING Phase 2 224 participants

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

NCT06203600

RECRUITING Phase 2 99 participants

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

Mayo Clinic

NCT06078709

RECRUITING NA 66 participants

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

University of Washington

NCT05911243

RECRUITING Phase 2 40 participants

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Roswell Park Cancer Institute

NCT05651594

RECRUITING Phase 1 24 participants

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

M.D. Anderson Cancer Center

NCT04615013

ACTIVE NOT RECRUITING Phase 2 43 participants

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

M.D. Anderson Cancer Center

NCT03784326

ACTIVE NOT RECRUITING Phase 1 16 participants

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

NRG Oncology

NCT04391049

COMPLETED NA 34 participants

Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study

Thomas Jefferson University

NCT04449679

COMPLETED 24 participants

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

Mayo Clinic

NCT04183218

COMPLETED 22 participants

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

City of Hope Medical Center

NCT04501913

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Clinical Stage II Esophageal Adenocarcinoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Biospecimen Collection Procedure
6 trials
Fluorouracil Drug
4 trials
Computed Tomography Procedure
4 trials
Questionnaire Administration Other
3 trials
Carboplatin Drug
3 trials
Radiation Therapy Radiation
2 trials
Paclitaxel Drug
2 trials
Capecitabine Drug
2 trials

US sites by state

Facility locations filed on Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trials. A trial with sites in several states counts in each.

Texas 3 trials
Florida 3 trials
California 3 trials
Arizona 3 trials
New York 2 trials
Arkansas 2 trials
Washington 1 trials
Pennsylvania 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Clinical Stage II Esophageal Adenocarcinoma AJCC v8 page

11 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 6 Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • NRG Oncology sponsors the most Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See NRG Oncology's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Clinical Stage II Esophageal Adenocarcinoma AJCC v8 condition card totals 11 registered trials; most-linked intervention Biospecimen Collection; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.